The biology and pathogenesis of hepatitis viruses

Current Science

Volumn 98, Issue 3, 2010, Pages 312-325

  Kumar, Vijay ^a   Das, Saumitra ^b   Jameel, Shahid ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Anti viral therapy; Hepatitis viruses; Hepatocellular carcinoma; Interferon therapy; Vaccine

Indexed keywords

HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 77953353067     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. Hollinger, F. B. and Emerson, S. U., Hepatitis A virus. In Field's Virology (eds Knipe, D. M. and Howley, P. M.), Lippincott, Williams and Wilkins, Philadelphia, 2007, pp. 911-948.
2. Seeger, C., Zoulim, F. and Mason, W. S., Hepadnaviruses. In Field's Virology (eds Knipe, D. M. and Howley, P. M.), Lippincott, Williams and Wilkins, Philadelphia, 2007, pp. 2977-3030.
3. Lemon, S. E., Walker, C. E., Alter, M. J. and Yi, M., Hepatitis C virus. In Field's Virology (eds Knipe, D. M. and Howley, P. M.), Lippincott, Williams and Wilkins, Philadelphia, 2007, pp. 1253-1304.
4. Taylor, J. M., Farci, P. and Purcell, R. H., Hepatitis D (Delta) virus. In Field's Virology (eds Knipe, D. M. and Howley, P. M.), Lippincott, Williams and Wilkins, Philadelphia, 2007, pp. 1691-1740.
5. Emerson, S. U. and Purcell, R. H., Hepatitis E virus. In Field's Virology (eds Knipe, D. M. and Howley, P. M.), Lippincott, Williams and Wilkins, Philadelphia, 2007, pp. 3047-3058.
6. Lednar, W. M. et al., Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am. J. Epidemiol., 1985, 122, 226-233.
7. Willner, I. R. et al., Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Annu. Intern. Med., 1998, 128, 111-114.
8. Cohen J. I. et al., Complete nucleotide sequence of wild type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J. Virol., 1987, 61, 50-59.
9. Shimizu, Y. K. et al., Localization of hepatitis A antigen in liver tissue by peroxidase-conjugated antibody method: Light and electron microscopy studies. J. Immunol., 1978, 121, 1671-1679.
10. Fleischer, B. et al., Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology, 1990, 69, 14-19.
11. Bowie, A. G. and Unterholzner, L., Viral evasion and subversion of pattern recognition receptor signaling. Nat. Rev. Immunol., 2008, 8, 911-922.
12. Martin, A. and Lemon, S. M., Hepatitis A virus: from discovery to vaccines. Hepatology, 2006, 43, S164-S172.
13. WHO, Prevention of hepatitis B in India, World Health Organization, New Delhi, 2002
14. Lau, J. Y. N. and Wright, T. L., Molecular virology and pathogenesis of hepatitis B virus. Lancet, 1993, 342, 1335-1340.
15. Sarin, S. K. et al., Profile of hepatocellular carcinoma in India: An insight into the possible etiologic associations. J. Gastroenterol. Hepatol., 2001, 16, 666-673.
16. Parkin, D. M. et al., Global cancer statistics, 2002. CA Cancer J. Clinol., 2005, 55, 74-106.
17. Kramvis, A. et al., Hepatitis B virus genotypes. Vaccine, 2005, 23, 2409-2423.
18. Kane, M. A., Global status of hepatitis B immunisation. Lancet, 1996, 348, 696.
19. Wong, D. K. et al., Effect of alpha-interferon treatment in patients with hepatitis B antigen positive chronic hepatitis B. A meta-analysis. Annu. Intern. Med., 1993, 119, 312.
20. Craxi, A. et al., Interferon alpha for HBeAg positive chronic hepatitis B: systematic review. J. Hepatol., 2003, 39, S99-S105.
21. Lai, C. L. et al., A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med., 1998, 339, 61-68.
22. Zoulim, F. and Perrillo, R., Hepatitis B: reflections on the current approach to antiviral therapy. J. Hepatol., 2008, 48, S2-S19.
23. Miller, R. H. et al., Compact organization of the hepatitis B virus genome. Hepatology, 1989, 9, 322-327.
24. Kumar, V. and Sarkar, D. P., Hepatitis B Virus X protein (HBx): structure-function relationships and role in viral pathogenesis. In Handbook of Experimental Pharmacology (eds Triezenberg, S. J., Kaufman, J. and Gossen, M.), Springer Verlag, Germany, 2004, pp. 377-407.
25. Bouchard, M. J. and Schneider, R. J., The enigmatic X gene of hepatitis B virus. J. Virol., 2004, 78, 12725-12734.
26. Beck, J. and Nassal, M., Hepatitis B virus replication. World J. Gastroenterol., 2007, 13, 48-64.
27. Centers for Disease Control and Prevention, Hepatitis B virus: a comprehensive strategy for limiting transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR, 1991, 40, 1-25.
28. Houghton, M., Discovery of the hepatitis C virus. Liver Int., 2009, 29, 82-88.
29. Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. and Bell, B. P., The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol., 2006, 45, 529-538.
30. Alter, M. J., Epidemiology of hepatitis C virus infection. World J. Gastroenterol., 2007, 13, 2436-2441.
31. Simmonds, P., Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol., 2004, 85, 3173-3188.
32. Acharya, S. K., Madan, K., Dattagupta, S. and Panda, S. K., Viral hepatitis in India. Natl. Med. J. India, 2006, 19, 203-217.
33. Panigrahi, A. K., Roca, J., Acharya, S. K., Jameel, S. and Panda, S. K., Genotype determination of hepatitis C virus from northern India: identification of a new subtype. J. Med. Virol., 1996, 48, 191-198.
34. Lole, K. S., Jha, J. A., Shrotri, S. P., Tandon, B. N., Prasad, V. G. and Arankalle, V. A., Comparison of hepatitis C virus genotyping by 5′ noncoding region and core-based reverse transcriptase PCR assay with sequencing and use of the assay for determining subtype distribution in India. J. Clin. Microbiol., 2003, 41, 5240-5244.
35. Singh, S., Malhotra, V. and Sarin, S. K., Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J. Med. Res., 2004, 119, 145-148.
36. Bhattacharyya, S. et al., Phylogenetic conservation of the stemloop III structure of the 5′ untranslated region of Hepatitis C virus RNA among natural variants in samples collected from Southern India. Arch. Virol., 2004, 149, 1015-1026.
37. Fried, M. W., Viral factors affecting the outcome of therapy for chronic hepatitis C. Rev. Gastroenterol. Disord., 2004, 4, S8-S13.
38. Hazari, S., Panda, S. K., Gupta, S. D., Batra, Y., Singh, R. and Acharya, S. K., Treatment of hepatitis C virus infection in patients of northern India. J. Gastroenterol. Hepatol., 2004, 19, 1058-1065.
39. Pawlotsky, J. M., The nature of interferon-alpha resistance in hepatitis C virus infection. Curr. Opin. Infect. Dis., 2003, 16, 587-592.
40. Gupta, R., Subramani, M., Khaja, M. N., Madhavi, C., Roy, S., Habibullah, C. M. and Das, S., Analysis of mutations within the 5′ untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India. J. Clin. Microbiol., 2006, 44, 709-715.
41. Suzuki, T., Ishii, K., Aizaki, H. and Wakita, T., Hepatitis C viral life cycle. Adv. Drug Deliv. Rev., 2007, 59, 1200-1212.
42. Suzuki, T., Aizaki, H., Murakami, K., Shoji, I. and Wakita, T., Molecular biology of hepatitis C virus. J. Gastroenterol., 2007, 42, 411-423.
43. Ploss, A., Evans, M. J., Gaysinskaya V. A., Panis, M., You, H., de Jong, Y. P. and Rice, C. M., Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature, 2009, 457, 882-886.
44. Bekker, V. et al., Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. J. Viral. Hepat., 7 August 2009 (Epub ahead of print).
45. Keck, Z. Y. et al., Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J. Virol., 2009, 83, 6149-6160.
46. Wang, C., Sarnow, P. and Siddiqui, A., Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J. Virol., 1993, 67, 3338-3344.
47. Kieft, J. S., Zhou, K., Jubin, R. and Doudna, J. A., Mechanism of ribosome recruitment by hepatitis C IRES RNA. RNA, 2001, 7, 194-206.
48. Fukushi, S., Okada, M., Stahl, J., Kageyama, T., Hoshino, F. B. and Katayama, K., Ribosomal protein S5 interacts with the internal ribosomal entry site of hepatitis C virus. J. Biol. Chem., 2001, 276, 20824-20826.
49. Pestova, T. V., Shatsky, I. N., Fletcher, S. P., Jackson, R. J. and Hellen, C. U. T., A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev., 1998, 12, 67-83.
50. Ali, N., Pruijn, G. J. M., Kenan, D. J., Keene, J. D. and Siddiqui, A., Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. J. Biol. Chem., 2000, 275, 27531-27540.
51. Costa-Mattioli, M., Svitkin, Y. and Sonenberg, N., La autoantigen is necessary for optimal function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in vitro. Mol. Cell. Biol., 2004, 24, 6861-6870.
52. Pudi, R., Abhiman, S., Srinivasan, N. and Das, S., Hepatitis C virus internal ribosome entry site-mediated translation is stimulated by specific interaction of independent regions of human La autoantigen. J. Biol. Chem., 2003, 278, 12231-12240.
53. Pudi, R., Srinivasan, P. and Das, S., La protein binding at the GCAC site near the initiator AUG facilitates the ribosomal assembly on the hepatitis C virus RNA to influence internal ribosome entry site-mediated translation. J. Biol. Chem., 2004, 279, 29879-29888.
54. Domitrovich, A. M., Diebel, K. W., Ali, N., Sarker, S. and Siddiqui, A., Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication. Virology, 2005, 335, 72-86.
55. Brass, V., Moradpour, D. and Blum, H. E., Hepatitis C virus infection: in vivo and in vitro models. J. Viral. Hepat., 2007, 14, 64-67.
56. Duverlie, G. and Wychowski, C., Cell culture systems for the hepatitis C virus. World J. Gastroenterol., 2007, 13, 2442-2445.
57. Murakami, K. et al., Production of infectious hepatitis C virus particles in three-dimensional cultures of the cell line carrying the genome-length dicistronic viral RNA of genotype 1b. Virology, 2006, 351, 381-392.
58. Saito, T., Owen, D. M., Jiang, F., Marcotrigiano, J. and Gale Jr, M., Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature, 2008, 454, 523-527.
59. Sällberg, M., Frelin, L. and Weiland, O., DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. Exp. Opin. Biol. Ther., 2009, 9, 5-15.
60. Chen, K. X. and Njoroge, F. G., A review of HCV protease inhibitors. Curr. Opin. Investig. Drugs, 2009, 10, 821-837.
61. Burton Jr, J. R. and Everson, G. T., HCV NS5B polymerase inhibitors. Clin. Liver. Dis., 2009, 13, 453-465.
62. Dasgupta, A., Das, S., Izumi, R., Venkatesan, A. and Barat, B., Targeting internal ribosome entry site (IRES)-mediated translation to block hepatitis C and other RNA viruses. FEMS Microbiol. Lett., 2004, 15, 189-199.
63. Ray, P. and Das, S., Inhibition of hepatitis C virus translation by small RNAs corresponding to stem-loop structures of the 5′ untranslated region by interaction with specific cellular proteins required for internal initiation. Nucleic Acids Res., 2004, 32, 1678-1687.
64. Roy, S., Gupta, N., Nithya, S., Mondal, T., Banerjee, A. and Das, S., Sequence specific cleavage of hepatitis C virus RNA by DNAenzymes: inhibition of viral RNA translation and replication. J. Gen. Virol., 2008, 89, 1579-1586.
65. Subramanian, N., Mani, P., Roy, S., Gnanasundram, S. V., Sarkar, D. P. and Das, S., Targeted delivery of hepatitis C virus specific shRNA in mouse liver using Sendai virosomes. J. Gen. Virol., 2009 (in press), Epub ahead of print.
66. Pudi, R., Sudhamoni, S. R. and Das, S., A peptide derived from RRM2 of human La protein binds to hepatitis C virus IRES, prevents ribosomal assembly and inhibits internal initiation of translation. J. Virol., 2005, 79, 9842-9853.
67. Mondal, T., Ray, U., Manna, A., Gupta, R., Roy, S. and Das, S., Structural determinant of human La protein critical for internal initiation of translation of hepatitis C virus RNA, J. Virol., 2008, 82, 11927-11938.
68. Rizzetto, M., Hepatitis D: thirty years after. J. Hepatol., 2009, 50, 1043-1050.
69. Rizzetto, M. et al., Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut, 1977, 18, 997-1003.
70. Fattovich, G. et al., Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European concerted action on viral hepatitis (Eurohep). Gut, 2000, 46, 420-426.
71. Salassa, B. et al., Serological diagnosis of hepatitis B and delta virus (HBV/HDV) coinfection. J. Hepatol., 1991, 12, 10-13.
72. Modahl, L. E. and Lai, M. M., Hepatitis delta virus: the molecular basis of laboratory diagnosis. Crit. Rev. Clin. Lab. Sci., 2000, 37, 45-92.
73. Dény, P., Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr. Top. Microbiol. Immunol., 2006, 307, 151-171.
74. Hsieh, T. H. et al., Natural course and treatment of hepatitis D virus infection. J. Formos. Med. Assoc., 2006, 105, 869-881.
75. Niro, G. A. et al., Treatment of hepatitis D., J. Viral. Hepat., 2005, 12, 2-9.
76. Hsieh, S. Y. et al., Hepatitis delta virus genome replication: a polyadenylated mRNA for delta antigen. J. Virol., 1990, 64, 3192-3198.
77. Chao, M. et al., Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. J. Virol., 1990, 64, 5066-5069.
78. Chang, F. L., The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. Proc. Natl. Acad. Sci. USA, 1991, 88, 8490-8494.
79. Taylor, J. M., The structure and replication of hepatitis delta virus. Annu. Rev. Microbiol., 1992, 46, 253-276.
80. Modahl, L. E. et al., RNA-dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases. Mol. Cell. Biol., 2000, 20, 6030-6039.
81. Wong, D. C. et al., Epidemic and enteric hepatitis in India: Evidence for non-A, non-B etiology. Lancet, 1980, 2, 876-879.
82. Somani, S. K. et al., A serological study of intrafamilial spread from patients with sporadic hepatitis E virus infection. J. Viral Hepatitis, 2003, 10, 446-449.
83. Tei, S. et al., Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet, 2003, 362, 371-373.
84. Feagins, A. R. et al., Detection and characterization of infectious hepatitis E virus from commercial pig livers sold in local grocery stores in the USA. J. Gen. Virol., 2007, 88, 912-917.
85. Aggarwal, R. and Krawczynski, K., Hepatitis E: an overview and recent advances in clinical and laboratory research. J. Gastroenterol. Hepatol., 2000, 15, 9-20.
86. Kumar, A. et al., Hepatitis E virus is responsible for decompensation of chronic liver disease in an endemic region. Indian J. Gastroenterol., 2004, 23, 59-62.
87. Dalton, H. R. et al., Hepatitis E: an emerging infection in developed countries. Lancet Infect. Dis., 2008, 8, 698-709.
88. Purcell, R. H. et al., Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine, 2003, 21, 2607-2615.
89. Shrestha, M. P. et al., Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med., 2007, 356, 895-903.
90. Reyes, G. R. et al., Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science, 1990, 247, 1335-1339.
91. Chandra, V. et al., Molecular biology and pathogenesis of hepatitis E virus. J. Biosci., 2008, 33, 451-464.
92. Surjit, M. et al., The ORF2 protein of hepatitis E virus binds the 5′ region of viral RNA. J. Virol., 2004, 78, 320-328.
93. Zafrullah, M. et al., Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein. J. Virol., 1999, 73, 4074-4082.
94. Graff, J. et al., Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles. J. Virol., 2008, 82, 1185-1194.
95. Emerson, S. U. and Purcell, R. H., Recombinant vaccines for hepatitis E. Trends Mol. Med., 2001, 7, 462-466.
96. Yamashita, T. et al., Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc. Natl. Acad. Sci. USA, 2009, 106, 12986-12991.
97. Guu, T. S. Y. et al., Structure of the hepatitis E virus-like particles suggests mechanisms for virus assembly and receptor binding. Proc. Natl. Acad. Sci. USA, 2009, 106, 12992-12997.
98. Kalia, M. et al., Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. J. Virol., 2009, doi:10.1128/JVI.00717-09 (Epub ahead of print).
99. Graff, J. et al., The open reading frame 3 gene of hepatitis E virus contains a cis-reactive element and encodes a protein required for infection of macaques. J. Virol., 2005, 79, 6680-6689.
100. Okamoto, H., Genetic variability and evolution of hepatitis E virus. Virus Res., 2007, 127, 216-228.
101. Takahashi, M. et al., Identification of two distinct genotypes of hepatitis E virus in a Japanese patient with acute hepatitis who had not travelled abroad. J. Gen. Virol., 2002, 83, 1931-1940.
102. Panda, S. K. et al., The in vitro-synthesized RNA from a cDNA clone of hepatitis E virus is infectious. J. Virol., 2000, 74, 2430-2437.
103. Emerson, S. U. et al., Recombinant hepatitis E virus genomes infectious for primates: importance of capping and discovery of a cis-reactive element. Proc. Natl. Acad. Sci. USA, 2001, 98, 15270-15275.
104. Huang, Y. W. et al., Capped RNA transcripts of full-length cDNA clones of swine hepatitis E virus are replication competent when transfected into Huh7 cells and infectious when intrahepatically inoculated into pigs. J. Virol., 2005, 79, 1552-1558.
105. Tanaka, T. et al., Development and evaluation of an efficient cellculture system for hepatitis E virus. J. Gen. Virol., 2007, 88, 903-911.
106. Soe, S. et al., Enterically transmitted non-A, non-B hepatitis in cynomolgus monkeys: morphology and probable mechanism of hepatocellular necrosis. Liver, 1989, 9, 135-145.
107. Khuroo, M. S. et al., Hepatitis E and long-term antibody status. Lancet, 1993, 341, 1355.
108. Tsarev, S. A. et al., Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc. Natl. Acad. Sci. USA, 1994, 91, 10198-10202.
109. Srivastava, R. et al., Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol., 2007, 20, 56-65.
110. Pal, R. et al., Immunological alterations in pregnant women with acute hepatitis E. J. Gastroenterol. Hepatol., 2005, 20, 1094-1101.
111. Deka, N. et al., Isolation of the novel agent from human stool samples that is associated with sporadic non-A, non-B hepatitis. J. Virol., 1994, 68, 7810-7815.
112. Reshetnyak, V. I. et al., Hepatitis G virus. World J. Gastroenterol., 2008, 14, 4725-4734.
113. Okamoto, H., History of discoveries and pathogenicity of TT viruses. Curr. Top. Microbiol. Immunol., 2009, 331, 1-20.
114. Akiba, J. et al., SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion, 2005, 45, 1084-1088.